

Executive Officer Notice

Pan-Canadian Competitive Value Price Initiative for Generic Drugs

March 15, 2016

Provinces and territories are continuing to work together to lower generic drug prices through the Pan-Canadian Competitive Value Price Initiative for Generic Drugs, which is a coordinated approach to price setting for generic drugs across Canada's provinces and territories.

In the past three years, the work of the Initiative resulted in the lowering of the prices of fourteen (14) high expenditure molecules to 18% of the brand price. The prices for these fourteen molecules will remain at 18% of the brand price for one (1) additional year.

In 2016, another three (3) generic molecules will be reduced to 18% of the brand price in Ontario:

- Donepezil
- Ezetimibe
- Quetiapine

The prices for these three generic molecules will have new Drug Benefit Prices, effective April 1, 2016.

The Ministry has posted a new file (Edition No. 42, Summary of Changes – April 1, 2016) with the listing changes for pharmacies to download and review. It is accessible from the Ministry's website at: [Visit: Formulary Downloads: Edition 42](#)

We appreciate your attention to this matter and continued cooperation in making these benefit adjustments.